Hansa Biopharma Reports Third Quarter and Interim Year to Date 2025 Financial Results

Imlifidase successfully met primary endpoint in pivotal US Phase 3 ConfIdeS trial in kidney transplantation. First clinical data supports imlifidase ability to substantially reduce anti-AAV antibodies to allow administration of gene therapy. LUND, Sweden, Oct. 30, 2025 /PRNewswire/ --...